EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Di-Chimeric Cell Therapy Derived From Hematopoietic and Mesenchymal Stem Cells Promotes Immune Tolerance and Extends Vascularized Composite Allograft Survival

Maria Siemionow, Safak Halil Uygur, Katarzyna Stawarz, Lucile Chambily, Katarzyna Budzynska, Weronika Radecka

Archivum Immunologiae et Therapiae Experimentalis · 2026

DOI: 10.2478/aite-2026-0013 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Archivum Immunologiae et Therapiae Experimentalis, 2026. Verfasst von Maria Siemionow und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopaedics, University of Illinois at Chicago, Chicago, IL, USA. Hauptthemen laut MEDLINE: Mesenchymal Stem Cells, Graft Rejection, Mesenchymal Stem Cell Transplantation, Hematopoietic Stem Cell Transplantation. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chimerism-based strategies remain promising for tolerance induction in solid organ and vascularized composite allograft (VCA) transplantation. This study aimed to develop a novel, less toxic chimeric cell therapy to prolong allograft survival and reduce the need for lifelong immunosuppression. Di-chimeric cells (DCC) were created via polyethylene glycol (PEG)-mediated ex vivo fusion of allogeneic hematopoietic stem cells (HSC) and mesenchymal stem cells (MSC) derived from August Copenhagen Irish (ACI) and Lewis rats. Twenty-four fully major histocompatibility complex (MHC)-mismatched groin flap VCAs were transplanted from ACI rat major histocompatibility complex (rat MHC) (RT1 a ) donors to Lewis (RT1 1 ) recipients under a 7-day immunosuppressive protocol of anti-αβTCR antibody and tacrolimus, combined with four different cell therapies of n = 6/group: Group 1, saline control; Group 2, MSC; Group 3, HSC/HSC DCC; and Group 4, HSC/MSC DCC. DCC were delivered via the intraosseous injection. DCC phenotype was confirmed by flow cytometry (FC). Graft rejection was evaluated macroscopically. A single DCC dose significantly prolonged VCA survival, with the best results in Group 4 (94 ± 1.65 days), followed by Group 3 (66 ± 1.24 days), Group 2 (45.5 ± 4.08 days), and Group 1 (38 ± 4.29 days). This study confirmed immunomodulatory and tolerogenic properties of DCC, supporting VCA transplantation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mesenchymal Stem CellsGraft RejectionMesenchymal Stem Cell TransplantationHematopoietic Stem Cell TransplantationHematopoietic Stem CellsVascularized Composite AllotransplantationComposite Tissue AllograftsCell- and Tissue-Based TherapyAnimalsGraft SurvivalRats, Inbred LewRatsImmune ToleranceRats, Inbred ACIHumansTransplantation ToleranceTransplantation, HomologousTransplantation ChimeraMaleImmunosuppressive Agents

Stichwörter der Autor:innen

Chimeric cell therapyChimerismHematopoietic stem cellsMesenchymal stem cellsTransplantationVascularized composite allograft

Substanzen

Immunosuppressive Agents

Autor:innen und Institutionen

  • Department of Orthopaedics, University of Illinois at Chicago, Chicago, IL, USA.

Zitieren

APA

Siemionow, M., Uygur, S. H., Stawarz, K., Chambily, L., Budzynska, K., & Radecka, W. (2026). Di-Chimeric Cell Therapy Derived From Hematopoietic and Mesenchymal Stem Cells Promotes Immune Tolerance and Extends Vascularized Composite Allograft Survival. Archivum Immunologiae et Therapiae Experimentalis. https://doi.org/10.2478/aite-2026-0013

Vancouver

Siemionow M, Uygur SH, Stawarz K, Chambily L, Budzynska K, Radecka W. Di-Chimeric Cell Therapy Derived From Hematopoietic and Mesenchymal Stem Cells Promotes Immune Tolerance and Extends Vascularized Composite Allograft Survival. Archivum Immunologiae et Therapiae Experimentalis. 2026. doi:10.2478/aite-2026-0013

BibTeX
@article{Siemionow2026,
  author = {Siemionow, Maria and Uygur, Safak Halil and Stawarz, Katarzyna and Chambily, Lucile and Budzynska, Katarzyna and Radecka, Weronika},
  title = {Di-Chimeric Cell Therapy Derived From Hematopoietic and Mesenchymal Stem Cells Promotes Immune Tolerance and Extends Vascularized Composite Allograft Survival},
  journal = {Archivum Immunologiae et Therapiae Experimentalis},
  year = {2026},
  doi = {10.2478/aite-2026-0013}
}
Kostenlos starten →